Synchron, a renowned developer of brain-computer interface (BCI) technology, has publicly announced the appointment of Riki Banerjee as its new Chief Technology Officer. Banerjee, who previously served as the Vice President of Research and Development at Synchron, brings a wealth of experience and expertise to her new role.
Upon joining Synchron in September 2021 following a successful 12-year tenure with Medtronic’s neurovascular operating unit, Banerjee has played a pivotal role in driving the company’s research and development activities. Her innovative contributions have been instrumental in advancing Synchron’s neuroprosthesis device, which is designed to assist patients with severe paralysis.
In a statement regarding Banerjee’s promotion, Synchron’s CEO and co-founder, Dr. Tom Oxley, expressed confidence in her leadership abilities, stating, “Riki has been an instrumental part of Synchron’s growth and has also been the driving force behind our product design. She is a senior leader at the intersection of neuromodulation innovation, engineering, implantable medical devices and commercialization. Her expertise and leadership will be transformative as we accelerate our Synchron BCI device toward the industry’s first pivotal study.”
In light of her new role, Banerjee will lead all of Synchron’s R&D activities, guiding the company’s efforts to bring its groundbreaking BCI technology to market. Her appointment comes at a pivotal time for Synchron, as the company recently completed enrollment for its COMMAND clinical trial after securing the first FDA investigational device exemption for assessment of a permanently implanted BCI. Synchron is now poised to undergo a pivotal study to attain FDA approval and bring its innovative neurotechnology to the public.
Reflecting on Synchron’s achievements, Banerjee stated, “Synchron has developed an elegant new way to deliver a neuroprosthesis device to the brain that avoids many of the barriers of more invasive BCI approaches. I’m excited to lead the R&D and product team at this pivotal time of growth to advance this innovative neurotechnology to patients. Synchron’s technology has the potential to change the lives of millions of people worldwide with upper limb impairment by delivering a first-in-class commercial BCI.”
Amidst these developments, Synchron has also expanded its board with the addition of former Dexcom CEO, Andy Rasdal. Rasdal brings with him a wealth of industry experience, having previously held executive roles at wearable developer Epitel and Medtronic’s vascular unit. His appointment to Synchron’s board further underscores the company’s commitment to driving innovation and expanding its reach within the healthcare sector.
As Synchron continues to make strides in the development and commercialization of its BCI technology, Banerjee’s leadership will undoubtedly play a crucial role in steering the company towards achieving its vision of transforming the lives of individuals with severe paralysis. Her appointment as Chief Technology Officer underscores Synchron’s unwavering dedication to pioneering advancements in neurotechnology and improving patient outcomes on a global scale.
+ There are no comments
Add yours